IBM Watson's AI is trying to find new cancer treatments IBM continued Watson's evolution on Thursday when the computing company announced it will use the artificial intelligence system to seek out new treatments for cancer patients. The plan also includes a partnership with drug-maker Pfizer, and for good reason: It will be one of the first companies to use Watson for drug research and the first to customize the A.I. for its own purposes. Pfizer will use Watson to "support the identification of new drug targets, combination therapies for study, and patient selection strategies in immuno-oncology." This collaboration is part of IBM's efforts to use Watson as a medical tool. The company said that the A.I. has "ingested" more than 1 million articles from medical journals, 4 million patents, and 25 million abstracts from Medline, a medical supplies manufacturer and distributor.

You may know Watson as IBM's Jeopardy-winning, cookbook-writing, dress-designing, weather-predicting supercomputer-of-all trades. Starting today, 40 organizations will rely upon the clever computers cognitive power to help spot cybercrime. The Watson for Cybersecurity beta program helps IBM too, because Watson's real-world experience will help it hone its skills and work within specific industries. After all, the threats that keep security experts at Sun Life Financial up at night differ from those that spook the cybersleuths at University of New Brunswick. IBM researchers started training Watson in the fundamentals of cybersecurity last spring so the computer could begin to analysize and prevent threats.

Want to watch this again later? Report Need to report the video? Report Need to report the video? Need to report the video? This feature is not available right now.

Want to watch this again later? Report Need to report the video? Report Need to report the video? Need to report the video? This feature is not available right now.

HARMAN participated at IBM's World of Watson event in Las Vegas to announce how we are integrating the cognitive technology capabilities of IBM Watson with HARMAN's powerful enterprise IOT solutions. Drawing on our extensive enterprise IOT solutions, HARMAN is providing the'central nervous system' to the IBM Watson'brain' for more intuitive, connected experiences in healthcare, hospitality and corporate settings. The result: voice enabled cognitive rooms by HARMAN. Mohit Parasher, executive vice president and president, Professional Solutions at HARMAN, participated on stage to discuss how HARMAN and IBM successfully tested a prototype voice-activated JBL speaker solution at Thomson Jefferson University Hospital in Philadelphia that allows patients to control their environment directly and answer questions with the goal of improving patient experiences and care. Eighty percent of physicians describe themselves as overextended or at capacity.

IBM's Deborah DiSanzo made the announcement at the 2016 Forbes Healthcare Summit. Immunotherapy is an approach that uses the immune system to fight diseases, unlike chemotherapy, which kills cancer cells. Immunotherapy works on cells in the immune system to combat cancer. Dario Gil, director of symbiotic cognitive systems at IBM Research, holds a remote control wand while giving a demonstration of the IBM Watson immersion room during an event at the company's headquarters in New York Oct. 7, 2014. By partnering with IBM's Watson for Drug Discovery, Pfizer hopes to more quickly analyze and test hypotheses from "massive volumes of disparate data sources" that include more than 30 million sources of laboratory and data reports as well as medical literature.

Immunotherapy is an approach that uses the immune system to fight diseases, unlike chemotherapy, which kills cancer cells. Immunotherapy works on cells in the immune system to combat cancer. Dario Gil, director of symbiotic cognitive systems at IBM Research, holds a remote control wand while giving a demonstration of the IBM Watson immersion room during an event at the company's headquarters in New York Oct. 7, 2014. By partnering with IBM's Watson for Drug Discovery, Pfizer hopes to more quickly analyze and test hypotheses from "massive volumes of disparate data sources" that include more than 30 million sources of laboratory and data reports as well as medical literature. Watson will also be able to combine such a massive database with Pfizer's own proprietary research information.

IBM companies Watson Health and Merge Healthcare unveiled several new machine learning and artificial intelligence technologies for imaging at the RSNA Annual meeting in Chicago this week. Big Blue also showcased new advancements in how Watson technology can learn and gain understanding from image information, which researchers say now accounts for some 90 percent of all medical data. IBM has taken a keen insight in applying Watson's supercomputing capabilities to imaging – especially since its 2015 acquisition of Merge. Big Blue, in fact, is developing numerous tools to help automate analytics, enabling cross-reference X-rays, MRIs and other images against electronic health record data, lab results, genomic tests and more. At RSNA, Watson Health is showcasing: a cognitive peer review tool aimed at reconciling differences between a patient's clinical evidence and data in his or her EHR; a data summarization tool meant to give radiologists, cardiologists and others patient-specific clinical information when they're interpreting imaging studies; a decision support tool to enable physicians to integrate imaging data with other clinical information; the new MedyMatch "Brain Bleed" App, a cognitive image review tool intended to help ER docs diagnose strokes or brain bleed in trauma patients based on evidence in their patient records.

There is plenty of growing evidence that market leaders are making Artificial Intelligence (AI) a top strategic priority and already seeing results. Most business leaders that have rolled our cognitive solutions expect to continue seeing tangible results, and gain a competitive advantage over the next few decades. The five most valuable companies in the United States by market capitalization (Apple, Alphabet/Google, Microsoft, Amazon and Facebook) focus heavily on AI within their research efforts and business models. The five most valuable companies in the United States by market capitalization (Apple, Alphabet/Google, Microsoft, Amazon and Facebook) focus heavily on AI within their research efforts and business models. A newly published IBM study found that the majority (58%) of early adopters of AI (and the cognitive systems that use AI capabilities) believe that these new technologies are "must haves" to remain competitive within the next few years.